BCL2L11 and cancer: In 2012, Ng reported that BIM deletion polymorphism mediated primary resistance to TKIs in cancers including chronic myeloid leukemia (CML) and EGFR‐mutant NSCLC; this; was confirmed by in vitro cell culture experiments and clinical data.14